

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

**Claim 1. (Currently Amended)** A method for the cytoprotective treatment of chronically obstructive lung, comprising administering to a subject in need thereof an effective dose of a combination consisting of

(a) ~~silibin~~ silibinin or a salt thereof  
and

(b)  $\alpha$ -lipoic acid or a salt thereof,  
and a pharmaceutical carrier for each (a) and (b),

wherein each of (a) and (b) are administered to said subject by inhalation in a simultaneous, separate, or timed manner.

**Claim 2. (Previously Presented)** The method according to claim 1, wherein said subject is a human patient and the dose of said  $\alpha$ -lipoic acid or a salt thereof is between 30 and 1800 mg/d.

**Claim 3. (Currently Amended)** The method according to Claim 1, wherein said subject is a human patient and the dose of said ~~silibin~~ silibinin or a salt thereof is between 20 and 1600 mg/d.

**Claim 4. (Cancelled)**

**Claim 5. (Currently Amended)** ~~The method according to Claim 1, comprising administering to said subject~~ A method for the cytoprotective treatment of chronically obstructive lung, comprising administering to a subject in need thereof an effective dose of a combination consisting of

(a) silibinin or a salt thereof,

(b)  $\alpha$ -lipoic acid or a salt thereof, and

(c) an additive which is an aqueous solvent, a stabilizer, a suspending agent, a dispersing agent or a wetting agent,

wherein each of (a), (b) and (c) are administered to said subject by inhalation in a simultaneous, separate, or timed manner.

**Claim 6. (Previously Presented)** The method according to Claim 1, wherein each of (a) and (b) is presented in the form of an aerosol.

**Claim 7. (Currently Amended)** The method according to Claim 1, wherein ~~silibinin~~ silibinin or a salt thereof and the  $\alpha$ -lipoic acid or a salt thereof is presented in a single formulation.

**Claim 8. (Currently Amended)** The method according to Claim 1, wherein ~~silibinin~~ silibinin or a salt thereof and the  $\alpha$ -lipoic acid or a salt thereof are presented in separate formulations.

**Claim 9. (Cancelled)**

**Claim 10. (Currently Amended)** The method according to Claim 1, wherein ~~an effector of glutathione metabolism~~ the silibinin or a salt thereof and the  $\alpha$ -lipoic acid or a salt thereof are presented in a single formulation.

**Claim 11. (Currently Amended)** The method according to Claim 1, wherein ~~an effector of glutathione metabolism~~ the silibinin or a salt thereof and the  $\alpha$ -lipoic acid or a salt thereof are presented in separate formulations.

**Claim 12. (Currently Amended)** ~~A~~ The method according to Claim 1, wherein the combination consists of  
(a) silibinin and  
(b)  $\alpha$ -lipoic acid, for the simultaneous, separate or timed cytoprotective treatment of chronically obstructive lung diseases comprising administering silibinin, its salts and/or its pro drugs with  $\alpha$ -lipoic acid

**Claim 13. (Previously Presented)** The method according to claim 2, wherein the dose of  $\alpha$ -lipoic acid or a salt thereof is between 200 and 600 mg/ d.

**Claim 14. (Currently Amended)** The method according to claim 3, wherein the dose of ~~silibinin~~ silibinin or a salt thereof is between 300 and 800 mg/ d.

**Claim 15. (Currently Amended)** The method according to Claim 1, wherein said subject is a human patient and the dose of said ~~silibin~~ silibinin or a salt thereof is between 20 and 1600 mg/d and the dose of said  $\alpha$ -lipoic acid or a salt thereof is between 30 and 1800 mg/d.